The efficacy of Pfizer and BioNTech’s Covid-19 vaccine on teens is fading in the weeks following vaccination, according to a study published Wednesday in JAMA Network Open, a finding that coincides with studies in adults as pharmaceutical companies modify their injections to target new coronavirus variants such as microns.
The efficacy of Pfizer’s covid vaccine “declined over time” and showed only “limited protection” as early as 30 days after the current dose, according to a peer-reviewed study of adolescents aged 12 to 18 in South Korea between July 2021 and July 2021. expired in January 2022.
Of the roughly 3. 2 million teens involved in the study, only about 29,300 tested positive for covid after vaccination and 11 were seriously ill and needed primary hospital, such as mechanical ventilation or kidney replacement therapy, the researchers said.
Unvaccinated adolescents made up a small fraction of the organization examined: more than 81% had won at least one injection, 75% had won double vaccination, and 9% had won a third dose, but accounted for more than a portion (55%) of adolescents. with an infection, adding the other 11 people with a serious illness.
The researchers said the findings are consistent with other studies showing that coverage against infection decreases after vaccination, but remains strong against serious illnesses.
The discovery of durable ions in the face of severe disease suggests that two doses of Pfizer’s vaccine might be enough for teens with severe illnesses, albeit with declining immunity, the researchers added.
The researchers note that the effects of the study may have been influenced by prospective changes in control habit based on vaccination prestige, the outbreak of omicron, other variants of the virus that spread the study, and differences in when other people were vaccinated.
The effects are not unexpected and are consistent with really extensive evidence that coverage against infection is brief after vaccination. Early trials of covid vaccines have failed to assess the duration of coverage provided by a vaccine beyond a few months or against the new evasive variants that dominate today. However, time has revealed that vaccines are offering high degrees of coverage against serious illness, hospitalization and death and that this is maintained for a much longer period of time. This, and not coverage against infection, experts are considered to be the most important function of vaccination. Boosters can also complement this coverage when it’s being activated, experts are divided on whether they’re needed for everyone or whether additional boosters are favorable for people at risk. groups
New vaccines. The widely used vaccines are based on the original strain of coronavirus discovered in 2020, a virus that differs particularly from the variants that are spreading today. Major vaccine brands like Pfizer and Moderna are introducing another generation of vaccines to target new variants for long-term booster campaigns. Some ongoing targets are the parent strain and a newer variant (the dual technique is known as a bivalent vaccine) and the UK is the first country to approve Moderna’s omicron/original booster vaccine.
“We push our way out” of the Covid pandemic, experts warn (Forbes)
Should you receive a Covid reminder? Here’s who should do it and how. (Forbe)
Pfizer’s Covid vaccine coverage against Omicron fades just weeks after the first and third doses, according to a (Forbes)
The Covid virus continues to evolve. Why are there no vaccines?(Wired)
Full Coronavirus Policy and Updates